Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 8/20 | 0.49 |
| ▸ | PTK6 | Q13882 | 5/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.39 |
| ▸ | CD38 | P28907 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8241616 | 0.84 | AURKA (0.64) | AURKAAURKBCD38MAPKAPK5 | |
| SCHEMBL8428012 | 0.84 | AURKA (0.47) | AURKAPTK6AURKBCD38CHEK1 | |
| SCHEMBL14507910 | 0.82 | AURKA (0.45) | AURKAPTK6AURKBCD38CHEK1 | |
| SCHEMBL14529971 | 0.82 | AURKA (0.45) | AURKAPTK6AURKBCD38CHEK1 | |
| SCHEMBL8250953 | 0.82 | AURKA (0.47) | AURKAPTK6AURKBLCKMAPKAPK5 | |
| SCHEMBL8240926 | 0.82 | AURKA (0.45) | AURKAPTK6AURKBCD38CHEK1 | |
| SCHEMBL8247986 | 0.82 | AURKA (0.45) | AURKAPTK6AURKBCD38CHEK1 | |
| SCHEMBL8246867 | 0.82 | AURKA (0.45) | AURKAPTK6AURKBCD38CHEK1 | |
| SCHEMBL8248254 | 0.80 | AURKB (0.53) | AURKAPTK6AURKBCHEK1LCK | |
| SCHEMBL8246925 | 0.79 | CHEK1 (0.46) | AURKAPTK6AURKBCD38CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576085-B2 | Imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2009-08-18 | — | — | US | disclosed |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | AURKA 91/4885PTK6 692/4885AURKB 137/4885 |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | CHEK1, CHEK2, CDKN1A | AURKA 41/4885PTK6 292/4885AURKB 138/4885 |
| US-20070105864-A1 | Methods for inhibiting protein kinases | PIM1, PIM2, PIM3 | AURKA 5/4885PTK6 443/4885AURKB 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.